Security key
432705200
Tharimmune, Inc. - Common Stock, $0.0001 par value (THAR)
CUSIP: 432705200
Q4 2023 13F Holders as of 31 Dec 2023
- Security type / class
- Equity / Common Stock, $0.0001 par value
- Total 13F shares
- 136,117
- Total 13F value
- $68,823
- Share change
- +136,117
- SEC-reported price per share
- $0.51
- Number of holders
- 5
- Value change
- +$68,823
- Number of buys
- 5
- Shares outstanding
- 2,660,728
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q4 2023
Institutions
5
Top holders
5
THAR full security history
Ownership snapshot
Full 13F holder table
Canton Strategic Holdings, Inc. SEC filings
Canton Strategic Holdings, Inc. company facts
Broader feeds
Ownership snapshot
Top reported holders of THAR - Tharimmune, Inc. - Common Stock, $0.0001 par value (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Highpoint Pharmaceuticals...
Disclosed value leader
Highpoint Pharmaceuticals...
Comparable rows
0/13
Latest evidence
30 Sep 2023
3/4/5
13F
Highest disclosed value: $489,028
13 rows are not safely comparable across share classes.
Showing 1-6 of 13 holder rows.
Quick read
Highpoint Pharmaceuticals LLC has the largest disclosed position value at $489K.
0 of 13 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Highpoint Pharmaceuticals LLC's linked filing trail.
Disclosed position value
Top 5
Highpoint Pharmaceuticals LLC
$489K
Kufe LLC
$407.6K
Surender Kharbanda
$362.8K
Varinder Kaur
$328.5K
Sandeep Laumas
$319.9K
Value bars compare disclosed positions; verify each figure against the linked filing evidence.
Detailed SEC evidence table Showing 1-6 of 13 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Highpoint Pharmaceuticals LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$489,028
972,222 shares
|
— | 11 Jan 2022 |
| Kufe LLC |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$407,629
810,395 shares
|
— | 11 Jan 2022 |
| Surender Kharbanda |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$362,784
721,240 shares
|
— | 11 Jan 2022 |
| Varinder Kaur |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$328,489
653,059 shares
|
— | 11 Jan 2022 |
| Sandeep Laumas |
3/4/5
10%+ Owner
|
—
class O/S missing
|
$319,912
636,008 shares
|
— | 11 Jan 2022 |
| TWO SIGMA SECURITIES, LLC |
13F
Company
|
—
class O/S missing
|
$11,414
57,070 shares
|
— | 30 Sep 2023 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2023
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
5
Shares
136,117
Rows available
5
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2023 vs Q3 2023 Across Filers
Q3 2023 holders
0
Q4 2023 holders
5
Holder diff
5
| Investor | Q3 2023 Shares | Q4 2023 Shares | Share Diff | Share Chg % | Q3 2023 value | Q4 2023 value | Value change | Value Chg % |
|---|